Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15285417 | 0.80 | FAAH (0.64) | ALOX5FAAHCA2EPHX1TSHR | |
| SCHEMBL2237283 | 0.80 | FAAH (0.64) | ALOX5FAAHCA2EPHX1TSHR | |
| SCHEMBL6219939 | 0.74 | CA2 (0.43) | ALOX5CYP1A2CA2 | |
| SCHEMBL1666626 | 0.74 | CXCR2 (0.60) | CA2 | |
| SCHEMBL1667673 | 0.74 | CXCR2 (0.60) | CA2 | |
| SCHEMBL7164190 | 0.74 | CA2 (0.43) | ALOX5CYP1A2CA2 | |
| SCHEMBL3875094 | 0.74 | EPHX1 (0.58) | ALOX5CYP1A2EPHX1CYP2D6TSHR | |
| SCHEMBL4493827 | 0.74 | EPHX1 (0.58) | ALOX5CYP1A2EPHX1CYP2D6TSHR | |
| SCHEMBL5249132 | 0.73 | FAAH (0.41) | ALOX5FAAHCA2EPHX1TSHR | |
| SCHEMBL5213717 | 0.73 | FAAH (0.41) | ALOX5FAAHCA2EPHX1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844001-B1 | METABOLITES OF 2-ARYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-06-10 | — | — | EP | disclosed |
| US-20090131441-A1 | Metabolites Of 2-Arylpropionic Acid Derivatives And Pharmaceutical Compositions Containing Them | DOMPE PHAR.R.MA S.P.A. (IT) | 2009-05-21 | — | — | US | disclosed |
| EP-1844001-A1 | METABOLITES OF 2-ARYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' pha.r.ma s.p.a. (IT) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006079624-A1 | METABOLITES OF 2-ARYLPROPIONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA. S.P.A. (IT) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131441-A1 | Metabolites Of 2-Arylpropionic Acid Derivatives And Pharmaceutical Compositions Containing Them | CXCR2, CXCR3, MMP8 | ALOX5 420/4885CYP1A2 817/4885FAAH 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.